δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches

Skeletal Muscle

Volumn 1, Issue 1, 2011, Pages

  Blain, Alison M ^a   Straub, Volker W ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

EID: 84856548628     PISSN: None     EISSN: 20445040     Source Type: Journal    
DOI: 10.1186/2044-5040-1-13     Document Type: Review

References (155)

1. Walton JN, Nattrass FJ. On the classification, natural history and treatment of the myopathies. Brain 1954, 77:169-231. 10.1093/brain/77.2.169, 13190076.
2. Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987, 51:919-928. 10.1016/0092-8674(87)90579-4, 3319190.
3. Monaco AP, Neve RL, Colletti-Feener C, Bertelson CJ, Kurnit DM, Kunkel LM. Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 1986, 323:646-650. 10.1038/323646a0, 3773991.
4. Campbell KP, Kahl SD. Association of dystrophin and an integral membrane glycoprotein. Nature 1989, 338:259-262. 10.1038/338259a0, 2493582.
5. Yoshida M, Noguchi S, Wakabayashi E, Piluso G, Belsito A, Nigro V, Ozawa E. The fourth component of the sarcoglycan complex. FEBS Lett 1997, 403:143-148. 10.1016/S0014-5793(97)00040-9, 9042955.
6. Nigro V, Piluso G, Belsito A, Politano L, Puca AA, Papparella S, Rossi E, Viglietto G, Esposito MG, Abbondanza C, Medici N, Molinari AM, Nigro G, Puca GA. Identification of a novel sarcoglycan gene at 5q33 encoding a sarcolemmal 35 kDa glycoprotein. Hum Mol Genet 1996, 5:1179-1186. 10.1093/hmg/5.8.1179, 8842738.
7. Nigro V, de Sá Moreira E, Piluso G, Vainzof M, Belsito A, Politano L, Puca AA, Passos-Bueno MR, Zatz M. Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the δ-sarcoglycan gene. Nat Genet 1996, 14:195-198. 10.1038/ng1096-195, 8841194.
8. Guglieri M, Magri F, D'Angelo MG, Prelle A, Morandi L, Rodolico C, Cagliani R, Mora M, Fortunato F, Bordoni A, Del Bo R, Ghezzi S, Pagliarani S, Lucchiari S, Salani S, Zecca C, Lamperti C, Ronchi D, Aguennouz M, Ciscato P, Di Blasi C, Ruggieri A, Moroni I, Turconi A, Toscano A, Moggio M, Bresolin N, Comi GP. Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients. Hum Mutat 2008, 29:258-266. 10.1002/humu.20642, 17994539.
9. Politano L, Nigro V, Passamano L, Petretta V, Comi LI, Papparella S, Nigro G, Rambaldi PF, Raia P, Pini A, Mora M, Giugliano MA, Esposito MG, Nigro G. Evaluation of cardiac and respiratory involvement in sarcoglycanopathies. Neuromuscul Disord 2001, 11:178-185. 10.1016/S0960-8966(00)00174-7, 11257475.
10. Fayssoil A. Cardiac diseases in sarcoglycanopathies. Int J Cardiol 2010, 144:67-68. 10.1016/j.ijcard.2008.12.048, 19157606.
11. Bushby K. Diagnosis and management of the limb girdle muscular dystrophies. Pract Neurol 2009, 9:314-323. 10.1136/jnnp.2009.193938, 19923111.
12. Fanin M, Duggan DJ, Mostacciuolo ML, Martinello F, Freda MP, Soraru G, Trevisan CP, Hoffman EP, Angelini C. Genetic epidemiology of muscular dystrophies resulting from sarcoglycan gene mutations. J Med Genet 1997, 34:973-977. 10.1136/jmg.34.12.973, 1051145, 9429136.
13. Norwood FL, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain 2009, 132:3175-3186. 10.1093/brain/awp236, 19767415.
14. Duggan DJ, Manchester D, Stears KP, Mathews DJ, Hart C, Hoffman EP. Mutations in the δ-sarcoglycan gene are a rare cause of autosomal recessive limb-girdle muscular dystrophy (LGMD2). Neurogenetics 1997, 1:49-58. 10.1007/s100480050008, 10735275.
15. Tsubata S, Bowles KR, Vatta M, Zintz C, Titus J, Muhonen L, Bowles NE, Towbin JA. Mutations in the human δ-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J Clin Invest 2000, 106:655-662. 10.1172/JCI9224, 381284, 10974018.
16. Trabelsi M, Kavian N, Daoud F, Commere V, Deburgrave N, Beugnet C, Llense S, Barbot JC, Vasson A, Kaplan JC, Leturcq F, Chelly J. Revised spectrum of mutations in sarcoglycanopathies. Eur J Hum Genet 2008, 16:793-803. 10.1038/ejhg.2008.9, 18285821.
17. Honda T, Sugiyama S, Sakamoto T, Kaikita K, Ogawa H. Impact of δ-sarcoglycan gene polymorphism on the occurrence of coronary spastic angina in Japanese patients with hypertrophic cardiomyopathy. Circ J 2007, 71:1263-1267. 10.1253/circj.71.1263, 17652892.
18. Kärkkäinen S, Miettinen R, Tuomainen P, Kärkkäinen P, Heliö T, Reissell E, Kaartinen M, Toivonen L, Nieminen MS, Kuusisto J, Laakso M, Peuhkurinen K. A novel mutation, Arg71Thr, in the δ-sarcoglycan gene is associated with dilated cardiomyopathy. J Mol Med 2003, 81:795-800.
19. Bauer R, Hudson J, Müller HD, Sommer C, Dekomien G, Bourke J, Routledge D, Bushby K, Klepper J, Straub V. Does δ-sarcoglycan-associated autosomal-dominant cardiomyopathy exist?. Eur J Hum Genet 2009, 17:1148-1153. 10.1038/ejhg.2009.17, 2986598, 19259135.
20. Chen J, Shi W, Zhang Y, Sokol R, Cai H, Lun M, Moore BF, Farber MJ, Stepanchick JS, Bönnemann CG, Chan YM. Identification of functional domains in sarcoglycans essential for their interaction and plasma membrane targeting. Exp Cell Res 2006, 312:1610-1625. 10.1016/j.yexcr.2006.01.024, 16524571.
21. Liu LA, Engvall E. Sarcoglycan isoforms in skeletal muscle. J Biol Chem 1999, 274:38171-38176. 10.1074/jbc.274.53.38171, 10608889.
22. Chan YM, Bönnemann CG, Lidov HG, Kunkel LM. Molecular organization of sarcoglycan complex in mouse myotubes in culture. J Cell Biol 1998, 143:2033-2044. 10.1083/jcb.143.7.2033, 2175228, 9864373.
23. Draviam RA, Shand SH, Watkins SC. The β-δ-core of sarcoglycan is essential for deposition at the plasma membrane. Muscle Nerve 2006, 34:691-701. 10.1002/mus.20640, 17036316.
24. Shi W, Chen Z, Schottenfeld J, Stahl RC, Kunkel LM, Chan YM. Specific assembly pathway of sarcoglycans is dependent on β- and δ-sarcoglycan. Muscle Nerve 2004, 29:409-419. 10.1002/mus.10566, 14981741.
25. Vainzof M, Passos-Bueno MR, Canovas M, Moreira ES, Pavanello RC, Marie SK, Anderson LV, Bönnemann CG, McNally EM, Nigro V, Kunkel LM, Zatz M. The sarcoglycan complex in the six autosomal recessive limb-girdle muscular dystrophies. Hum Mol Genet 1996, 5:1963-1969. 10.1093/hmg/5.12.1963, 8968750.
26. Klinge L, Dekomien G, Aboumousa A, Charlton R, Epplen JT, Barresi R, Bushby K, Straub V. Sarcoglycanopathies: can muscle immunoanalysis predict the genotype?. Neuromuscul Disord 2008, 18:934-941. 10.1016/j.nmd.2008.08.003, 18996010.
27. Straub V, Ettinger AJ, Durbeej M, Venzke DP, Cutshall S, Sanes JR, Campbell KP. ε-Sarcoglycan replaces α-sarcoglycan in smooth muscle to form a unique dystrophin-glycoprotein complex. J Biol Chem 1999, 274:27989-27996. 10.1074/jbc.274.39.27989, 10488149.
28. Durbeej M, Campbell KP. Biochemical characterization of the epithelial dystroglycan complex. J Biol Chem 1999, 274:26609-26616. 10.1074/jbc.274.37.26609, 10473626.
29. Wheeler MT, Zarnegar S, McNally EM. ζ-sarcoglycan, a novel component of the sarcoglycan complex, is reduced in muscular dystrophy. Hum Mol Genet 2002, 11:2147-2154. 10.1093/hmg/11.18.2147, 12189167.
30. Anastasi G, Cutroneo G, Sidoti A, Rinaldi C, Bruschetta D, Rizzo G, D'Angelo R, Tarone G, Amato A, Favaloro A. Sarcoglycan subcomplex expression in normal human smooth muscle. J Histochem Cytochem 2007, 55:831-843. 10.1369/jhc.6A7145.2007, 17438352.
31. Anastasi G, Cutroneo G, Sidoti A, Santoro G, D'Angelo R, Rizzo G, Rinaldi C, Giacobbe O, Bramanti P, Navarra G, Amato A, Favaloro A. Sarcoglycan subcomplex in normal human smooth muscle: an immunohistochemical and molecular study. Int J Mol Med 2005, 16:367-374.
32. Anastasi G, Cutroneo G, Trimarchi F, Rizzo G, Bramanti P, Bruschetta D, Fugazzotto D, Cinelli MP, Soscia A, Santoro G, Favaloro A. Sarcoglycans in human skeletal muscle and human cardiac muscle: a confocal laser scanning microscope study. Cells Tissues Organs 2003, 173:54-63. 10.1159/000068217, 12566627.
33. Matsumura K, Saito F, Yamada H, Hase A, Sunada Y, Shimizu T. Sarcoglycan complex: a muscular supporter of dystroglycan-dystrophin interplay?. Cell Mol Biol (Noisy-le-grand) 1999, 45:751-762.
34. Wakayama Y, Inoue M, Kojima H, Murahashi M, Shibuya S, Oniki H. Localization of sarcoglycan, neuronal nitric oxide synthase, β-dystroglycan, and dystrophin molecules in normal skeletal myofiber: triple immunogold labeling electron microscopy. Microsc Res Tech 2001, 55:154-163. 10.1002/jemt.1166, 11747090.
35. Fanin M, Tasca E, Nascimbeni AC, Angelini C. Sarcolemmal neuronal nitric oxide synthase defect in limb-girdle muscular dystrophy: an adverse modulating factor in the disease course?. J Neuropathol Exp Neurol 2009, 68:383-390. 10.1097/NEN.0b013e31819cd612, 19287313.
36. Grozdanovic Z, Baumgarten HG. Nitric oxide synthase in skeletal muscle fibers: a signaling component of the dystrophin-glycoprotein complex. Histol Histopathol 1999, 14:243-256.
37. Chen J, Skinner MA, Shi W, Yu QC, Wildeman AG, Chan YM. The 16 kDa subunit of vacuolar H+-ATPase is a novel sarcoglycan-interacting protein. Biochim Biophys Acta 2007, 1772:570-579.
38. Anastasi G, Cutroneo G, Rizzo G, Arco A, Santoro G, Bramanti P, Vitetta AG, Pisani A, Trimarchi F, Favaloro A. Sarcoglycan and integrin localization in normal human skeletal muscle: a confocal laser scanning microscope study. Eur J Histochem 2004, 48:245-252.
39. Anastasi G, Amato A, Tarone G, Vita G, Monici MC, Magaudda L. Distribution and localization of vinculin-talin-integrin system and dystrophin-glycoprotein complex in human skeletal muscle. Cells Tissues Organs 2003, 175:151-164. 10.1159/000074631, 14663158.
40. Estrada FJ, Mornet D, Rosas-Vargas H, Angulo A, Hernández M, Becker V, Rendón A, Ramos-Kuri M, Coral-Vázquez RM. A novel isoform of δ-sarcoglycan is localized at the sarcoplasmic reticulum of mouse skeletal muscle. Biochem Biophys Res Commun 2006, 340:865-871. 10.1016/j.bbrc.2005.12.083, 1952693, 16403451.
41. Cai H, Erdman RA, Zweier L, Chen J, Shaw JH, Baylor KA, Stecker MM, Carey DJ, Chan YM. The sarcoglycan complex in Schwann cells and its role in myelin stability. Exp Neurol 2007, 205:257-269. 10.1016/j.expneurol.2007.02.015, 17397833.
42. Groh S, Zong H, Goddeeris MM, Lebakken CS, Venzke D, Pessin JE, Campbell KP. Sarcoglycan complex: implications for metabolic defects in muscular dystrophies. J Biol Chem 2009, 284:19178-19182. 10.1074/jbc.C109.010728, 2740540, 19494113.
43. Fort P, Estrada FJ, Bordais A, Mornet D, Sahel JA, Picaud S, Vargas HR, Coral-Vázquez RM, Rendon A. The sarcoglycan-sarcospan complex localization in mouse retina is independent from dystrophins. Neurosci Res 2005, 53:25-33. 10.1016/j.neures.2005.05.007, 1952695, 15993965.
44. Homburger F, Baker JR, Nixon CW, Wilgram G. New hereditary disease of Syrian hamsters: primary, generalized polymyopathy and cardiac necrosis. Arch Intern Med 1962, 110:660-662.
45. Jung D, Duclos F, Apostol B, Straub V, Lee JC, Allamand V, Venzke DP, Sunada Y, Moomaw CR, Leveille CJ, Slaughter CA, Crawford TO, McPherson JD, Campbell KP. Characterization of δ-sarcoglycan, a novel component of the oligomeric sarcoglycan complex involved in limb-girdle muscular dystrophy. J Biol Chem 1996, 271:32321-32329. 10.1074/jbc.271.50.32321, 8943294.
46. Nigro V, Okazaki Y, Belsito A, Piluso G, Matsuda Y, Politano L, Nigro G, Ventura C, Abbondanza C, Molinari AM, Acampora D, Nishimura M, Hayashizaki Y, Puca GA. Identification of the Syrian hamster cardiomyopathy gene. Hum Mol Genet 1997, 6:601-607. 10.1093/hmg/6.4.601, 9097966.
47. Straub V, Duclos F, Venzke DP, Lee JC, Cutshall S, Leveille CJ, Campbell KP. Molecular pathogenesis of muscle degeneration in the δ-sarcoglycan-deficient hamster. Am J Pathol 1998, 153:1623-1630. 10.1016/S0002-9440(10)65751-3, 1853419, 9811355.
48. Awad SS, Welty JD. Comparisons of hemodynamics throughout the life span of the Bio 14.6 cardiomyopathic with the F1B normal hamster. Comp Biochem Physiol A Comp Physiol 1990, 97:487-491. 10.1016/0300-9629(90)90115-9, 1981030.
49. Sakamoto A, Ono K, Abe M, Jasmin G, Eki T, Murakami Y, Masaki T, Toyo-oka T, Hanaoka F. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, δ-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. Proc Natl Acad Sci USA 1997, 94:13873-13878. 10.1073/pnas.94.25.13873, 28400, 9391120.
50. Sakamoto A. Molecular pathogenesis of severe cardiomyopathy in the TO-2 hamster. Exp Clin Cardiol 2003, 8:143-146. 2716276, 19641707.
51. Minieri M, Zingarelli M, Shubeita H, Vecchini A, Binaglia L, Carotenuto F, Fantini C, Fiaccavento R, Masuelli L, Coletti A, Simonelli L, Modesti A, Di Nardo P. Identification of a new missense mutation in the mtDNA of hereditary hypertrophic, but not dilated cardiomyopathic hamsters. Mol Cell Biochem 2003, 252:73-81. 10.1023/A:1025542731335, 14577578.
52. Heydemann A, Ceco E, Lim JE, Hadhazy M, Ryder P, Moran JL, Beier DR, Palmer AA, McNally EM. Latent TGF-β-binding protein 4 modifies muscular dystrophy in mice. J Clin Invest 2009, 119:3703-3712. 10.1172/JCI39845, 2786802, 19884661.
53. Swaggart KA, Heydemann A, Palmer AA, McNally EM. Distinct genetic regions modify specific muscle groups in muscular dystrophy. Physiol Genomics 2011, 43:24-31. 10.1152/physiolgenomics.00172.2010, 20959497.
54. Kawada T, Nakatsuru Y, Sakamoto A, Koizumi T, Shin WS, Okai-Matsuo Y, Suzuki J, Uehara Y, Nakazawa M, Sato H, Ishikawa T, Toyo-oka T. Strain- and age-dependent loss of sarcoglycan complex in cardiomyopathic hamster hearts and its re-expression by δ-sarcoglycan gene transfer in vivo. FEBS Lett 1999, 458:405-408. 10.1016/S0014-5793(99)01164-3, 10570949.
55. Gouveia TL, Kossugue PM, Paim JF, Zatz M, Anderson LV, Nigro V, Vainzof M. A new evidence for the maintenance of the sarcoglycan complex in muscle sarcolemma in spite of the primary absence of δ-SG protein. J Mol Med 2007, 85:415-420. 10.1007/s00109-007-0163-8, 17265058.
56. Hack AA, Lam MY, Cordier L, Shoturma DI, Ly CT, Hadhazy MA, Hadhazy MR, Sweeney HL, McNally EM. Differential requirement for individual sarcoglycans and dystrophin in the assembly and function of the dystrophin-glycoprotein complex. J Cell Sci 2000, 113:2535-2544.
57. Coral-Vazquez R, Cohn RD, Moore SA, Hill JA, Weiss RM, Davisson RL, Straub V, Barresi R, Bansal D, Hrstka RF, Williamson R, Campbell KP. Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell 1999, 98:465-474. 10.1016/S0092-8674(00)81975-3, 10481911.
58. Bauer R, MacGowan GA, Blain A, Bushby K, Straub V. Steroid treatment causes deterioration of myocardial function in the δ-sarcoglycan-deficient mouse model for dilated cardiomyopathy. Cardiovasc Res 2008, 79:652-661. 10.1093/cvr/cvn131, 18495669.
59. Bauer R, Blain A, Greally E, Bushby K, Lochmüller H, Laval S, Straub V, MacGowan GA. Intolerance to β-blockade in a mouse model of δ-sarcoglycan-deficient muscular dystrophy cardiomyopathy. Eur J Heart Fail 2010, 12:1163-1170. 10.1093/eurjhf/hfq129, 20675662.
60. Wansapura JP, Millay DP, Dunn RS, Molkentin JD, Benson DW. Magnetic resonance imaging assessment of cardiac dysfunction in δ-sarcoglycan null mice. Neuromuscul Disord 2011, 21:68-73. 10.1016/j.nmd.2010.09.007, 20934875.
61. Poppe M, Cree L, Bourke J, Eagle M, Anderson LV, Birchall D, Brockington M, Buddles M, Busby M, Muntoni F, Wills A, Bushby K. The phenotype of limb-girdle muscular dystrophy type 2I. Neurology 2003, 60:1246-1251.
62. Chambers SP, Anderson LV, Maguire GM, Dodd A, Love DR. Sarcoglycans of the zebrafish: orthology and localization to the sarcolemma and myosepta of muscle. Biochem Biophys Res Commun 2003, 303:488-495. 10.1016/S0006-291X(03)00355-3, 12659844.
63. Dekkers LC, van der Plas MC, van Loenen PB, den Dunnen JT, van Ommen GJ, Fradkin LG, Noordermeer JN. Embryonic expression patterns of the Drosophila dystrophin-associated glycoprotein complex orthologs. Gene Expr Patterns 2004, 4:153-159. 10.1016/j.modgep.2003.09.004, 15161095.
64. Grisoni K, Martin E, Gieseler K, Mariol MC, Segalat L. Genetic evidence for a dystrophin-glycoprotein complex (DGC) in Caenorhabditis elegans. Gene 2002, 294:77-86. 10.1016/S0378-1119(02)00762-X, 12234669.
65. Allikian MJ, Bhabha G, Dospoy P, Heydemann A, Ryder P, Earley JU, Wolf MJ, Rockman HA, McNally EM. Reduced life span with heart and muscle dysfunction in Drosophila sarcoglycan mutants. Hum Mol Genet 2007, 16:2933-2943. 10.1093/hmg/ddm254, 17855453.
66. Cheng L, Guo XF, Yang XY, Chong M, Cheng J, Li G, Gui YH, Lu DR. δ-Sarcoglycan is necessary for early heart and muscle development in zebrafish. Biochem Biophys Res Commun 2006, 344:1290-1299. 10.1016/j.bbrc.2006.03.234, 16650823.
67. Guyon JR, Mosley AN, Jun SJ, Montanaro F, Steffen LS, Zhou Y, Nigro V, Zon LI, Kunkel LM. δ-Sarcoglycan is required for early zebrafish muscle organization. Exp Cell Res 2005, 304:105-115. 10.1016/j.yexcr.2004.10.032, 15707578.
68. Segalat L. Dystrophin and functionally related proteins in the nematode Caenorhabditis elegans. Neuromuscul Disord 2002, 12(Suppl 1):S105-S109. 10.1016/S0960-8966(02)00090-1, 12206804.
69. Millay DP, Goonasekera SA, Sargent MA, Maillet M, Aronow BJ, Molkentin JD. Calcium influx is sufficient to induce muscular dystrophy through a TRPC-dependent mechanism. Proc Natl Acad Sci USA 2009, 106:19023-19028. 10.1073/pnas.0906591106, 2776441, 19864620.
70. Mendell JR, Sahenk Z, Prior TW. The childhood muscular dystrophies: diseases sharing a common pathogenesis of membrane instability. J Child Neurol 1995, 10:150-159. 10.1177/088307389501000219, 7782608.
71. Li M, Dickson DW, Spiro AJ. Sarcolemmal defect and subsarcolemmal lesion in a patient with γ-sarcoglycan deficiency. Neurology 1998, 50:807-809.
72. Pestronk A, Parhad IM, Drachman DB, Price DL. Membrane myopathy: morphological similarities to Duchenne muscular dystrophy. Muscle Nerve 1982, 5:209-214. 10.1002/mus.880050306, 7088018.
73. Kawada T, Hemmi C, Fukuda S, Tezuka A, Iwasawa K, Nakazawa M, Sato H, Toyo-oka T. Sarcolemmal fragility secondary to the degradation of dystrophin in dilated cardiomyopathy, as estimated by electron microscopy. Exp Clin Cardiol 2003, 8:67-70. 2716201, 19641652.
74. Sen LY, O'Neill M, Marsh JD, Smith TW. Myocyte structure, function, and calcium kinetics in the cardiomyopathic hamster heart. Am J Physiol 1990, 259:H1533-H1543.
75. Li GR, Ferrier GR, Howlett SE. Calcium currents in ventricular myocytes of prehypertrophic cardiomyopathic hamsters. Am J Physiol 1995, 268:H999-H1005.
76. Iwata Y, Katanosaka Y, Shijun Z, Kobayashi Y, Hanada H, Shigekawa M, Wakabayashi S. Protective effects of Ca2+ handling drugs against abnormal Ca2+ homeostasis and cell damage in myopathic skeletal muscle cells. Biochem Pharmacol 2005, 70:740-751. 10.1016/j.bcp.2005.05.034, 16009351.
77. Howlett SE, Rafuse VF, Gordon T. [3H]-Nitrendipine binding sites in normal and cardiomyopathic hamsters: absence of a selective increase in putative calcium channels in cardiomyopathic hearts. Cardiovasc Res 1988, 22:840-846. 10.1093/cvr/22.11.840, 2855722.
78. Tawada-Iwata Y, Imagawa T, Yoshida A, Takahashi M, Nakamura H, Shigekawa M. Increased mechanical extraction of T-tubule/junctional SR from cardiomyopathic hamster heart. Am J Physiol 1993, 264:H1447-H1453.
79. Sen L, Smith TW. T-type Ca2+ channels are abnormal in genetically determined cardiomyopathic hamster hearts. Circ Res 1994, 75:149-155.
80. Bkaily G, Sculptoreanu A, Jacques D, Jasmin G. Increases of T-type Ca2+ current in heart cells of the cardiomyopathic hamster. Mol Cell Biochem 1997, 176:199-204. 10.1023/A:1006832608377, 9406162.
81. Suzuki S, Ohkusa T, Ono K, Sato T, Yoshida MA, Yano M, Takebayashi S, Matsuzaki M. Beneficial effects of the dual L- and T-type Ca2+ channel blocker efonidipine on cardiomyopathic hamsters. Circ J 2007, 71:1970-1976. 10.1253/circj.71.1970, 18037756.
82. Villame J, Massicotte J, Jasmin G, Dumont L. Effects of mibefradil, a T- and L-type calcium channel blocker, on cardiac remodeling in the UM-X7.1 cardiomyopathic hamster. Cardiovasc Drugs Ther 2001, 15:41-48. 10.1023/A:1011158717901, 11504162.
83. Paquette F, Jasmin G, Dumont L. Cardioprotective efficacy of verapamil and mibefradil in young UM-X7.1 cardiomyopathic hamsters. Cardiovasc Drugs Ther 1999, 13:525-530. 10.1023/A:1007879704878, 10686662.
84. Ducret T, Vandebrouck C, Cao ML, Lebacq J, Gailly P. Functional role of store-operated and stretch-activated channels in murine adult skeletal muscle fibres. J Physiol 2006, 575:913-924. 10.1113/jphysiol.2006.115154, 1995676, 16825296.
85. Nakamura TY, Iwata Y, Sampaolesi M, Hanada H, Saito N, Artman M, Coetzee WA, Shigekawa M. Stretch-activated cation channels in skeletal muscle myotubes from sarcoglycan-deficient hamsters. Am J Physiol Cell Physiol 2001, 281:C690-C699.
86. Gervásio OL, Whitehead NP, Yeung EW, Phillips WD, Allen DG. TRPC1 binds to caveolin-3 and is regulated by Src kinase: role in Duchenne muscular dystrophy. J Cell Sci 2008, 121:2246-2255.
87. Ward ML, Williams IA, Chu Y, Cooper PJ, Ju YK, Allen DG. Stretch-activated channels in the heart: contributions to length-dependence and to cardiomyopathy. Prog Biophys Mol Biol 2008, 97:232-249. 10.1016/j.pbiomolbio.2008.02.009, 18367238.
88. Kuo TH, Tsang W, Wiener J. Defective Ca2+-pumping ATPase of heart sarcolemma from cardiomyopathic hamster. Biochim Biophys Acta 1987, 900:10-16. 10.1016/0005-2736(87)90272-0, 2954583.
89. Solares-Pérez A, Alvarez R, Crosbie RH, Vega-Moreno J, Medina-Monares J, Estrada FJ, Ortega A, Coral-Vazquez R. Altered calcium pump and secondary deficiency of γ-sarcoglycan and microspan in sarcoplasmic reticulum membranes isolated from δ-sarcoglycan knockout mice. Cell Calcium 2010, 48:28-36.
90. Babick AP, Cantor EJ, Babick JT, Takeda N, Dhalla NS, Netticadan T. Cardiac contractile dysfunction in J2N-k cardiomyopathic hamsters is associated with impaired SR function and regulation. Am J Physiol Cell Physiol 2004, 287:C1202-C1208. 10.1152/ajpcell.00155.2004, 15229104.
91. Thakar JH, Thede A, Strickland KP. On the ultrastructure of primary cultures of normal and dystrophic hamster tongue muscle. Muscle Nerve 1980, 3:340-344. 10.1002/mus.880030411, 7412777.
92. Makita T, Sasaki K. A possible mode of formation of mitochondrial dense bodies in cardiac muscle of a dystrophic hamster. Cytobios 1979, 25:183-192.
93. Fraysse B, Nagi SM, Boher B, Ragot H, Lainé J, Salmon A, Fiszman MY, Toussaint M, Fromes Y. Ca2+ overload and mitochondrial permeability transition pore activation in living δ-sarcoglycan-deficient cardiomyocytes. Am J Physiol Cell Physiol 2010, 299:C706-C713. 10.1152/ajpcell.00545.2009, 20592245.
94. Wrogemann K, Blanchaer MC, Thakar JH, Mezon BJ. On the role of mitochondria in the hereditary cardiomyopathy of the Syrian hamster. Recent Adv Stud Cardiac Struct Metab 1975, 6:231-241.
95. Wrogemann K, Nylen EG. Mitochondrial calcium overloading in cardiomyopathic hamsters. J Mol Cell Cardiol 1978, 10:185-195. 10.1016/0022-2828(78)90042-1, 204795.
96. Markiewicz W, Wu SS, Parmley WW, Higgins CB, Sievers R, James TL, Wikman-Coffelt J, Jasmin G. Evaluation of the hereditary Syrian hamster cardiomyopathy by 31P nuclear magnetic resonance spectroscopy: improvement after acute verapamil therapy. Circ Res 1986, 59:597-604.
97. Markiewicz W, Wu S, Sievers R, Parmley WW, Higgins CB, James TL, Jasmin G, Wikman-Coffelt J. Influence of heart rate on metabolic and hemodynamic parameters in the Syrian hamster cardiomyopathy. Am Heart J 1987, 114:362-368. 10.1016/0002-8703(87)90504-7, 3604893.
98. Millay DP, Sargent MA, Osinska H, Baines CP, Barton ER, Vuagniaux G, Sweeney HL, Robbins J, Molkentin JD. Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat Med 2008, 14:442-447. 10.1038/nm1736, 2655270, 18345011.
99. York CM, Cantrell CR, Borum PR. Cardiac carnitine deficiency and altered carnitine transport in cardiomyopathic hamsters. Arch Biochem Biophys 1983, 221:526-533. 10.1016/0003-9861(83)90171-6, 6838206.
100. Kobayashi A, Masumura Y, Yamazaki N. L-Carnitine treatment for congestive heart failure: experimental and clinical study. Jpn Circ J 1992, 56:86-94.
101. Maresca P, Corsico N, Arrigoni-Martelli E, Mancinelli R, Manni E. Propionyl-L-carnitine improves mechanical performance of papillary muscle from dilated cardiomyopathic hamsters. Ann N Y Acad Sci 1995, 752:207-209. 10.1111/j.1749-6632.1995.tb17425.x, 7755262.
102. Vargiu R, Littarru GP, Faa G, Mancinelli R. Positive inotropic effect of coenzyme Q10, ω-3 fatty acids and propionyl-L-carnitine on papillary muscle force-frequency responses of BIO TO-2 cardiomyopathic Syrian hamsters. Biofactors 2008, 32:135-144. 10.1002/biof.5520320116, 19096109.
103. Whitmer JT. L-Carnitine treatment improves cardiac performance and restores high-energy phosphate pools in cardiomyopathic Syrian hamster. Circ Res 1987, 61:396-408.
104. Yamashita T, Kobayashi A, Yamazaki N, Miura K, Shirasawa H. Effects of L-carnitine and verapamil on myocardial carnitine concentration and histopathology of Syrian hamster BIO 14.6. Cardiovasc Res 1986, 20:614-620. 10.1093/cvr/20.8.614, 3791351.
105. Vargiu R, Littarru GP, Fraschini M, Perinu A, Tiano L, Capra A, Mancinelli R. Enhancement of shortening velocity, power, and acto-myosin crossbridge (CB) kinetics following long-term treatment with propionyl-L-carnitine, coenzyme Q10, and ω-3 fatty acids in BIO TO-2 cardiomyopathic Syrian hamsters papillary muscle. Biofactors 2010, 36:229-239. 10.1002/biof.95, 20533397.
106. Keith ME, Ball A, Jeejeebhoy KN, Kurian R, Butany J, Dawood F, Wen WH, Madapallimattam A, Sole MJ. Conditioned nutritional deficiencies in the cardiomyopathic hamster heart. Can J Cardiol 2001, 17:449-458.
107. Jamall IS, Haldar D, Wadewitz AG. Effects of dietary selenium on lipid peroxidation, mitochondrial function and protein profiles in the heart of the myopathic Syrian golden hamster (BIO 14.6). Biochem Biophys Res Commun 1987, 144:815-820. 10.1016/S0006-291X(87)80037-2, 3579942.
108. Sembrowich WL, Knudson MB, Gollnick PD. Muscle metabolism and cardiac function of the myopathic hamster following training. J Appl Physiol 1977, 43:936-941.
109. Ho KW, Carrow R, Taylor J, Roy R, Lindstrom J, Heusner W, Van Huss W. Effects of swimming on dystrophic Syrian hamster heart. Exp Pathol (Jena) 1975, 11:247-254.
110. Tatsuguchi M, Hiratsuka E, Machida S, Nishikawa T, Imamura S, Shimizu S, Nishimura M, Komuro I, Furutani Y, Furutani M, Nagao H, Komatsu K, Kasanuki H, Matsuoka R. Swimming exercise in infancy has beneficial effect on the hearts in cardiomyopathic Syrian hamsters. J Muscle Res Cell Motil 2004, 25:69-76. 10.1023/B:JURE.0000021353.82449.9e, 15160490.
111. Durbeej M, Sawatzki SM, Barresi R, Schmainda KM, Allamand V, Michele DE, Campbell KP. Gene transfer establishes primacy of striated vs. smooth muscle sarcoglycan complex in limb-girdle muscular dystrophy. Proc Natl Acad Sci USA 2003, 100:8910-8915. 10.1073/pnas.1537554100, 166412, 12851463.
112. Figulla HR, Vetterlein F, Glaubitz M, Kreuzer H. Inhomogenous capillary flow and its prevention by verapamil and hydralazine in the cardiomyopathic Syrian hamster. Circulation 1987, 76:208-216.
113. Factor SM, Minase T, Cho S, Dominitz R, Sonnenblick EH. Microvascular spasm in the cardiomyopathic Syrian hamster: a preventable cause of focal myocardial necrosis. Circulation 1982, 66:342-354.
114. Cohn RD, Durbeej M, Moore SA, Coral-Vazquez R, Prouty S, Campbell KP. Prevention of cardiomyopathy in mouse models lacking the smooth muscle sarcoglycan-sarcospan complex. J Clin Invest 2001, 107:R1-R7. 10.1172/JCI11642, 199179, 11160141.
115. Sonnenblick EH, Fein F, Capasso JM, Factor SM. Microvascular spasm as a cause of cardiomyopathies and the calcium-blocking agent verapamil as potential primary therapy. Am J Cardiol 1985, 55:179B-184B. 10.1016/0002-9149(85)90629-0, 3881912.
116. Kobayashi A, Yamashita T, Kaneko M, Nishiyama T, Hayashi H, Yamazaki N. Effects of verapamil on experimental cardiomyopathy in the Bio 14.6 Syrian hamster. J Am Coll Cardiol 1987, 10:1128-1138. 10.1016/S0735-1097(87)80356-X, 2822790.
117. Wheeler MT, Allikian MJ, Heydemann A, Hadhazy M, Zarnegar S, McNally EM. Smooth muscle cell-extrinsic vascular spasm arises from cardiomyocyte degeneration in sarcoglycan-deficient cardiomyopathy. J Clin Invest 2004, 113:668-675. 351323, 14991064.
118. Shimizu T, Okamoto H, Watanabe M, Kumamoto H, Chiba S, Matsui Y, Sugawara T, Onozuka H, Mikami T, Kitabatake A. Altered microvasculature is involved in remodeling processes in cardiomyopathic hamsters. Jpn Heart J 2003, 44:111-126. 10.1536/jhj.44.111, 12622443.
119. Johnson P, Hammer JL. Calpain and calpastatin levels in dystrophic hamster skeletal muscles. Int J Biochem 1988, 20:1227-1230. 10.1016/0020-711X(88)90223-6, 2854796.
120. Crosbie RH, Barresi R, Campbell KP. Loss of sarcolemma nNOS in sarcoglycan-deficient muscle. FASEB J 2002, 16:1786-1791. 10.1096/fj.02-0519com, 12409321.
121. Sanders DB, Kelley T, Larson D. The role of nitric oxide synthase/nitric oxide in vascular smooth muscle control. Perfusion 2000, 15:97-104.
122. Rando TA. Role of nitric oxide in the pathogenesis of muscular dystrophies: a "two hit" hypothesis of the cause of muscle necrosis. Microsc Res Tech 2001, 55:223-235. 10.1002/jemt.1172, 11748861.
123. Crespo MJ, Cruz N, Altieri PI, Escobales N. Enalapril and losartan are more effective than carvedilol in preventing dilated cardiomyopathy in the Syrian cardiomyopathic hamster. J Cardiovasc Pharmacol Ther 2008, 13:199-206. 10.1177/1074248408320006, 18593848.
124. Abraham SS, Osorio JC, Homma S, Wang J, Thaker HM, Liao JK, Mital S. Simvastatin preserves cardiac function in genetically determined cardiomyopathy. J Cardiovasc Pharmacol 2004, 43:454-461. 10.1097/00005344-200403000-00018, 2643377, 15076231.
125. Crespo MJ, De Mello WC. Chronic administration of losartan plus hydrochlorothiazide improves vascular status in young cardiomyopathic hamsters. Eur J Pharmacol 2001, 420:133-141. 10.1016/S0014-2999(01)01006-8, 11408035.
126. Shinohara T, Shimizu M, Yoshio H, Ino H, Taguchi T, Mabuchi H. Collagen synthesis by cultured cardiac fibroblasts obtained from cardiomyopathic hamsters. Jpn Heart J 1998, 39:97-108.
127. Escobales N, Ramos JA, Santacana GE, Crespo MJ. Hemodynamic alterations in the coronary circulation of cardiomyopathic hamsters: age and Ang II-dependent mechanisms. J Card Fail 2009, 15:929-938. 10.1016/j.cardfail.2009.06.441, 2786781, 19944371.
128. Galla JH, Schneider G, Kotchen TA, Hayslett JP. Renin and aldosterone in the cardiomyopathic hamster in congestive heart failure. Endocrinology 1977, 101:389-395. 10.1210/endo-101-2-389, 885111.
129. Araki T, Shimizu M, Yoshio H, Ino H, Mabuchi H, Takeda R. Effects of angiotensin-converting enzyme inhibitor and aldosterone antagonist on myocardial collagen in cardiomyopathic hamsters. Jpn Circ J 1995, 59:213-218.
130. De Mello WC, Specht P. Chronic blockade of angiotensin II AT1-receptors increased cell-to-cell communication, reduced fibrosis and improved impulse propagation in the failing heart. J Renin Angiotensin Aldosterone Syst 2006, 7:201-205. 10.3317/jraas.2006.038, 17318788.
131. Mansoor AM, Honda M, Kuramochi T, Tanaka K, Morioka S, Takabatake T. Effects of ACE inhibition and beta-blockade on collagen remodelling in the heart of Bio 14.6 hamsters. Clin Exp Pharmacol Physiol 1996, 23:43-49. 10.1111/j.1440-1681.1996.tb03060.x, 8713495.
132. Lecarpentier Y, Pery N, Coirault C, Scalbert E, Desche P, Suard I, Lambert F, Chemla D. Intrinsic alterations of diaphragm muscle in experimental cardiomyopathy. Am Heart J 1993, 126:770-776. 10.1016/0002-8703(93)90928-3, 8362752.
133. Peng H, Carretero OA, Vuljaj N, Liao TD, Motivala A, Peterson EL, Rhaleb NE. Angiotensin-converting enzyme inhibitors: a new mechanism of action. Circulation 2005, 112:2436-2445. 10.1161/CIRCULATIONAHA.104.528695, 16216963.
134. Sejerson T, Bushby K, . TREAT-NMD EU Network of Excellence Standards of care for Duchenne muscular dystrophy: brief TREAT-NMD recommendations. Adv Exp Med Biol 2009, 652:13-21. full_text, 20225016, TREAT-NMD EU Network of Excellence.
135. Townsend D, Yasuda S, Li S, Chamberlain JS, Metzger JM. Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. Mol Ther 2008, 16:832-835. 10.1038/mt.2008.52, 2592846, 18414480.
136. Kawada T, Nakazawa M, Nakauchi S, Yamazaki K, Shimamoto R, Urabe M, Nakata J, Hemmi C, Masui F, Nakajima T, Suzuki J, Monahan J, Sato H, Masaki T, Ozawa K, Toyo-oka T. Rescue of hereditary form of dilated cardiomyopathy by rAAV-mediated somatic gene therapy: amelioration of morphological findings, sarcolemmal permeability, cardiac performances, and the prognosis of TO-2 hamsters. Proc Natl Acad Sci USA 2002, 99:901-906. 10.1073/pnas.022641799, 117403, 11805334.
137. Li J, Dressman D, Tsao YP, Sakamoto A, Hoffman EP, Xiao X. rAAV vector-mediated sarcogylcan gene transfer in a hamster model for limb girdle muscular dystrophy. Gene Ther 1999, 6:74-82. 10.1038/sj.gt.3300830, 10341878.
138. Holt KH, Lim LE, Straub V, Venzke DP, Duclos F, Anderson RD, Davidson BL, Campbell KP. Functional rescue of the sarcoglycan complex in the BIO 14.6 hamster using δ-sarcoglycan gene transfer. Mol Cell 1998, 1:841-848. 10.1016/S1097-2765(00)80083-0, 9660967.
139. Ikeda Y, Gu Y, Iwanaga Y, Hoshijima M, Oh SS, Giordano FJ, Chen J, Nigro V, Peterson KL, Chien KR, Ross J. Restoration of deficient membrane proteins in the cardiomyopathic hamster by in vivo cardiac gene transfer. Circulation 2002, 105:502-508. 10.1161/hc0402.102953, 11815435.
140. Toyo-oka T, Kawada T, Xi H, Nakazawa M, Masui F, Hemmi C, Nakata J, Tezuka A, Iwasawa K, Urabe M, Monahan J, Ozawa K. Gene therapy prevents disruption of dystrophin-related proteins in a model of hereditary dilated cardiomyopathy in hamsters. Heart Lung Circ 2002, 11:174-181. 10.1046/j.1444-2892.2002.00151.x, 16352094.
141. Li J, Wang D, Qian S, Chen Z, Zhu T, Xiao X. Efficient and long-term intracardiac gene transfer in δ-sarcoglycan-deficiency hamster by adeno-associated virus-2 vectors. Gene Ther 2003, 10:1807-1813. 10.1038/sj.gt.3302078, 12960970.
142. Goehringer C, Rutschow D, Bauer R, Schinkel S, Weichenhan D, Bekeredjian R, Straub V, Kleinschmidt JA, Katus HA, Müller OJ. Prevention of cardiomyopathy in δ-sarcoglycan knockout mice after systemic transfer of targeted adeno-associated viral vectors. Cardiovasc Res 2009, 82:404-410.
143. Hoshijima M, Hayashi T, Jeon YE, Fu Z, Gu Y, Dalton ND, Ellisman MH, Xiao X, Powell FL, Ross J. δ-Sarcoglycan gene therapy halts progression of cardiac dysfunction, improves respiratory failure, and prolongs life in myopathic hamsters. Circ Heart Fail 2011, 4:89-97. 10.1161/CIRCHEARTFAILURE.110.957258, 21036890.
144. Ying Y, Müller OJ, Goehringer C, Leuchs B, Trepel M, Katus HA, Kleinschmidt JA. Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library. Gene Ther 2010, 17:980-990. 10.1038/gt.2010.44, 20393510.
145. Mendell JR, Rodino-Klapac LR, Rosales-Quintero X, Kota J, Coley BD, Galloway G, Craenen JM, Lewis S, Malik V, Shilling C, Byrne BJ, Conlon T, Campbell KJ, Bremer WG, Viollet L, Walker CM, Sahenk Z, Clark KR. Limb-girdle muscular dystrophy type 2D gene therapy restores α-sarcoglycan and associated proteins. Ann Neurol 2009, 66:290-297. 10.1002/ana.21732, 19798725.
146. Mendell JR, Rodino-Klapac LR, Rosales XQ, Coley BD, Galloway G, Lewis S, Malik V, Shilling C, Byrne BJ, Conlon T, Campbell KJ, Bremer WG, Taylor LE, Flanigan KM, Gastier-Foster JM, Astbury C, Kota J, Sahenk Z, Walker CM, Clark KR. Sustained α-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 2010, 68:629-638. 10.1002/ana.22251, 21031578.
147. Nomura T, Ashihara E, Tateishi K, Asada S, Ueyama T, Takahashi T, Matsubara H, Oh H. Skeletal myosphere-derived progenitor cell transplantation promotes neovascularization in δ-sarcoglycan knockdown cardiomyopathy. Biochem Biophys Res Commun 2007, 352:668-674. 10.1016/j.bbrc.2006.11.097, 17150187.
148. Shabbir A, Zisa D, Leiker M, Johnston C, Lin H, Lee T. Muscular dystrophy therapy by nonautologous mesenchymal stem cells: muscle regeneration without immunosuppression and inflammation. Transplantation 2009, 87:1275-1282. 10.1097/TP.0b013e3181a1719b, 2746453, 19424025.
149. Henning RJ, Aufman J, Shariff M, Sawmiller D, DeLostia V, Sanberg P, Morgan M. Human umbilical cord blood mononuclear cells decrease fibrosis and increase cardiac function in cardiomyopathy. Regen Med 2010, 5:45-54. 10.2217/rme.09.71, 20017693.
150. Toyo-oka T, Kawada T, Nakata J, Xie H, Urabe M, Masui F, Ebisawa T, Tezuka A, Iwasawa K, Nakajima T, Uehara Y, Kumagai H, Kostin S, Schaper J, Nakazawa M, Ozawa K. Translocation and cleavage of myocardial dystrophin as a common pathway to advanced heart failure: a scheme for the progression of cardiac dysfunction. Proc Natl Acad Sci USA 2004, 101:7381-7385. 10.1073/pnas.0401944101, 409927, 15128945.
151. Nishizawa T, Iwase M, Kanazawa H, Ichihara S, Ichihara G, Nagata K, Obata K, Kitaichi K, Yokoi T, Watanabe M, Tsunematsu T, Ishikawa Y, Murohara T, Yokota M. Serial alterations of β-adrenergic signaling in dilated cardiomyopathic hamsters: possible role of myocardial oxidative stress. Circ J 2004, 68:1051-1060. 10.1253/circj.68.1051, 15502388.
152. Hampton TG, Kale A, Amende I, McCue S, Bhagavan HN, VanDongen CG. Gait disturbances in BIO TO-2 hamster model for muscular dystrophy [abstract]. FASEB J 2008, 22:757. 32.
153. Mitsuhashi S, Saito N, Watano K, Igarashi K, Tagami S, Shima H, Kikuchi K. Defect of δ-sarcoglycan gene is responsible for development of dilated cardiomyopathy of a novel hamster strain, J2N-k: calcineurin/PP2B activity in the heart of J2N-k hamster. J Biochem 2003, 134:269-276. 10.1093/jb/mvg140, 12966077.
154. Jasmin G, Bajusz E. Prevention of myocardial generation in hamsters with hereditary cardiomyopathy. Recent Adv Stud Cardiac Struct Metab 1975, 6:219-229.
155. Hunter EG, Hughes V, White J. Cardiomyopathic hamsters, CHF 146 and CHF 147: a preliminary study. Can J Physiol Pharmacol 1984, 62:1423-1428.